HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
26 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
RPS2
ribosomal protein S2
Chromosome 16 · 16p13.3
NCBI Gene: 6187Ensembl: ENSG00000140988.17HGNC: HGNC:10404UniProt: P15880
344PubMed Papers
20Diseases
6Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Highly StudiedTrending
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
nucleolusRNA bindingmRNA bindingstructural constituent of ribosomeinfluenzaDuchenne muscular dystrophycystic fibrosisatrial fibrillation
✦AI Summary

RPS2 (ribosomal protein S2) is a structural component of the small ribosomal subunit (40S) essential for protein synthesis 1. As part of the 40S subunit, RPS2 participates in mRNA binding and translation initiation, while also playing roles in nucleolar processing of pre-18S ribosomal RNA and ribosome assembly 1. RPS2 protein stability is tightly regulated through ubiquitin-mediated degradation; during ribosome-associated quality control (RQC), RPS2 is monoubiquitinated by the E3 ligase ZNF598 in response to ribosome collisions, and subsequently deubiquitinated by the G3BP1-family-USP10 complex to prevent lysosomal degradation 2. RPS2 is also subject to regulatory protein-protein interactions involving PDCD2 family proteins and PRMT3-mediated arginine methylation 3. Clinically, RPS2 dysregulation associates with multiple cancers: it is significantly upregulated in glioblastoma where RACK1 stabilizes RPS2 to promote NF-κB pathway activation and cell proliferation 4; hypomethylation and elevated RPS2 expression occur in hepatocellular carcinoma, supporting oncogenic functions 5; and RPS2 is a core component of a ribosome biogenesis signature predicting poor prognosis in clear cell renal cell carcinoma 6. Additionally, RPS2 expression is upregulated at the blood-brain barrier in Alzheimer's disease patients 7, and RPS2 represents a core gene associated with ischemic stroke pathology 8.

Sources cited
1
RPS2 component of small ribosomal subunit participating in mRNA translation and nucleolar pre-18S rRNA processing
PMID: 23636399
2
RPS2 monoubiquitination by ZNF598 during ribosome quality control and deubiquitination by G3BP1-family-USP10 complex
PMID: 31981475
3
RPS2 (uS5) protein-protein interactions with PDCD2, PDCD2L, PRMT3, and ZNF277; PRMT3-mediated arginine methylation
PMID: 37238722
4
RPS2 upregulation in glioblastoma; RACK1-mediated RPS2 stabilization promotes NF-κB pathway and cell proliferation
PMID: 40522528
5
RPS2 promoter hypomethylation and elevated expression in hepatocellular carcinoma with oncogenic roles
PMID: 38181486
6
RPS2 as core ribosome biogenesis gene in clear cell renal cell carcinoma prognostic signature
PMID: 40642093
7
RPS2 upregulation in brain capillaries of Alzheimer's disease patients
PMID: 35766008
8
RPS2 identified as core gene associated with ischemic stroke pathology
PMID: 37603533
Disease Associationsⓘ20
influenzaOpen Targets
0.46Moderate
Duchenne muscular dystrophyOpen Targets
0.46Moderate
cystic fibrosisOpen Targets
0.39Weak
atrial fibrillationOpen Targets
0.39Weak
severe acute respiratory syndromeOpen Targets
0.37Weak
COVID-19Open Targets
0.37Weak
neurodegenerative diseaseOpen Targets
0.25Weak
aniridiaOpen Targets
0.10Suggestive
Becker muscular dystrophyOpen Targets
0.10Suggestive
non-Hodgkins lymphomaOpen Targets
0.09Suggestive
genetic disorderOpen Targets
0.09Suggestive
hepatitis B virus infectionOpen Targets
0.08Suggestive
acute myeloid leukemiaOpen Targets
0.08Suggestive
Alport syndromeOpen Targets
0.07Suggestive
arthritisOpen Targets
0.07Suggestive
cystinosisOpen Targets
0.07Suggestive
Dravet syndromeOpen Targets
0.07Suggestive
hemophilia AOpen Targets
0.07Suggestive
hemophilia BOpen Targets
0.07Suggestive
muscular dystrophyOpen Targets
0.07Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets6
ATALURENApproved
80S Ribosome modulator
Duchenne muscular dystrophy
CITATUZUMAB BOGATOXPhase I
Epithelial cell adhesion molecule binding agent
ELX-02Phase II
80S Ribosome modulator
cystic fibrosis
MT-3724Phase II
80S Ribosome inhibitor
diffuse large B-cell lymphoma
TELIMOMAB ARITOXPhase II
T-cell surface glycoprotein CD5 binding agent
hepatitis B virus infection
ZOLIMOMAB ARITOXPhase II
T-cell surface glycoprotein CD5 binding agent
arthritis
Related Genes
EEF2Protein interaction100%EIF5AProtein interaction100%ETF1Protein interaction100%FANCEProtein interaction100%FAUProtein interaction100%FLT3LGProtein interaction100%
Tissue Expression6 tissues
Ovary
100%
Lung
53%
Liver
38%
Brain
34%
Bone Marrow
33%
Heart
18%
Gene Interaction Network
Click a node to explore
RPS2EEF2EIF5AETF1FANCEFAUFLT3LG
PROTEIN STRUCTURE
Preparing viewer…
PDB8GLP · 1.67 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.49Moderately Constrained
pLIⓘ
0.98Intolerant
Observed/Expected LoF0.23 [0.12–0.49]
RankingsWhere RPS2 stands among ~20K protein-coding genes
  • #931of 20,598
    Most Researched344 · top 5%
  • #771of 1,025
    FDA-Approved Drug Targets1
  • #2,913of 17,882
    Most Constrained (LOEUF)0.49 · top quartile
Genes detectedRPS2
Sources retrieved26 papers
Response time—
📄 Sources
26▼
1
The G3BP1-Family-USP10 Deubiquitinase Complex Rescues Ubiquitinated 40S Subunits of Ribosomes Stalled in Translation from Lysosomal Degradation.
PMID: 31981475
Mol Cell · 2020
1.00
2
Upregulation of ribosome complexes at the blood-brain barrier in Alzheimer's disease patients.
PMID: 35766008
J Cereb Blood Flow Metab · 2022
0.90
3
Identification of Key Genes and Pathways in Osteosarcoma by Bioinformatics Analysis.
PMID: 35075370
Comput Math Methods Med · 2022
0.84
4
RACK1 promotes NF-κB pathway activation and glioma cell proliferation by inhibiting RPS2 ubiquitination.
PMID: 40522528
Mol Biol Rep · 2025
0.80
5
Exploration of RNA-binding proteins identified RPS27 as a potential regulator associated with Kaposi's sarcoma development.
PMID: 40016701
BMC Cancer · 2025
0.70